Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

Vor Biopharma (NASDAQ:VOR) had its target price raised by Wedbush to $15.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Jefferies Financial Group assumed coverage on shares of Vor Biopharma in a report on Monday. They set a “buy” rating and a $50.00 target price for the company. Citigroup started coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 target price for the company. Wells Fargo & Company assumed coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, JPMorgan Chase & Co. reduced their price target on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.67.

Vor Biopharma Trading Up 21.4%

Shares of NASDAQ VOR opened at $17.84 on Tuesday. The firm has a market capitalization of $185.71 million, a PE ratio of -0.05 and a beta of 1.99. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80. The firm’s 50-day moving average is $14.19 and its 200-day moving average is $17.73.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vor Biopharma in the 4th quarter valued at approximately $36,000. Goldman Sachs Group Inc. raised its holdings in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after buying an additional 58,247 shares during the period. XTX Topco Ltd bought a new position in Vor Biopharma in the second quarter valued at approximately $66,000. Chung Wu Investment Group LLC bought a new position in Vor Biopharma in the fourth quarter valued at approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in shares of Vor Biopharma in the fourth quarter valued at approximately $134,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).